Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 28215665

11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet
Publication date
2017 Mar 25
First author
Cameron D

This record carries publication-notice metadata. Review the notices below before relying on it.

Publication notices

absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet. 2017 Mar 25;389(10075):1167-1168. doi: 10.1016/S0140-6736(17)30322-7.
    note
    Source null
    related pmid
    28215659
    relationship
    Comment in
  2. citation
    Lancet. 2018 Dec 23;390(10114):2767. doi: 10.1016/S0140-6736(17)31954-2.
    note
    Source null
    related pmid
    29303721
    relationship
    Comment in
  3. citation
    Lancet. 2018 Dec 23;390(10114):2767-2768. doi: 10.1016/S0140-6736(17)31940-2.
    note
    Source null
    related pmid
    29303722
    relationship
    Comment in
  4. citation
    Lancet. 2019 Mar 16;393(10176):1100. doi: 10.1016/S0140-6736(18)32771-5.
    note
    Source null
    related pmid
    30894267
    relationship
    Erratum in

Authors and identifiers

  1. name
    Cameron D
    type
    Author
  2. name
    Piccart-Gebhart MJ
    type
    Author
  3. name
    Gelber RD
    type
    Author
  4. name
    Procter M
    type
    Author
  5. name
    Goldhirsch A
    type
    Author
  6. name
    de Azambuja E
    type
    Author
  7. name
    Castro G Jr
    type
    Author
  8. name
    Untch M
    type
    Author
  9. name
    Smith I
    type
    Author
  10. name
    Gianni L
    type
    Author
  11. name
    Baselga J
    type
    Author
  12. name
    Al-Sakaff N
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Cameron D
    type
    Author
  2. name
    Piccart-Gebhart MJ
    type
    Author
  3. name
    Gelber RD
    type
    Author
  4. name
    Procter M
    type
    Author
  5. name
    Goldhirsch A
    type
    Author
  6. name
    de Azambuja E
    type
    Author
  7. name
    Castro G Jr
    type
    Author
  8. name
    Untch M
    type
    Author
  9. name
    Smith I
    type
    Author
  10. name
    Gianni L
    type
    Author
  11. name
    Baselga J
    type
    Author
  12. name
    Al-Sakaff N
    type
    Author
bibliography ids
  1. nci-bib-66ec7628bdb3f1dc25c0f54a
book metadata
content sha256
d191e7be2b4f5165d93fd33c1a8c9c8339a17597223126a29045ece191ede678
document type
citation
dois
  1. 10.1016/S0140-6736(16)32616-2
electronic publication date
display
2017 Feb 17
precision
day
year
2017
evidence scope
bibliographic_metadata_only
id
pubmed:28215665
immutable id
pubmed:28215665@d191e7be2b4f5165d93fd33c1a8c9c8339a17597223126a29045ece191ede678
journal
abbreviation
Lancet
issn electronic
1474-547X
issn print
0140-6736
issue
10075
name
Lancet (London, England)
nlm unique id
2985213R
pages
1195-1205
volume
389
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet. 2017 Mar 25;389(10075):1167-1168. doi: 10.1016/S0140-6736(17)30322-7.
    note
    Source null
    related pmid
    28215659
    relationship
    Comment in
  2. citation
    Lancet. 2018 Dec 23;390(10114):2767. doi: 10.1016/S0140-6736(17)31954-2.
    note
    Source null
    related pmid
    29303721
    relationship
    Comment in
  3. citation
    Lancet. 2018 Dec 23;390(10114):2767-2768. doi: 10.1016/S0140-6736(17)31940-2.
    note
    Source null
    related pmid
    29303722
    relationship
    Comment in
  4. citation
    Lancet. 2019 Mar 16;393(10176):1100. doi: 10.1016/S0140-6736(18)32771-5.
    note
    Source null
    related pmid
    30894267
    relationship
    Erratum in
outcomes validated
false
pmid
28215665
provenance
batch id
7a1288ac8bb5f9826304
provider
NCBI PubMed ESummary
record sha256
8b9c660cbfdc20ba55fb9846737018fe2a01fcf316890b6e7b8b5fe1407c6760
response sha256
0e879bec8c19d1cfda5629dca8745b04155d18cf54361825d4c070aebad2984d
retrieved at
2026-09-09T23:47:23.138359+00:00
publication date
display
2017 Mar 25
precision
day
year
2017
publication types
  1. Clinical Trial, Phase III
  2. Journal Article
  3. Multicenter Study
  4. Randomized Controlled Trial
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/28215665/
title
11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial.

Preserved source evidence · Not medical advice